An inhibitor of xanthine oxidoreductase
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Topiroxostat

Item No. 21267

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-[3-(4-pyridinyl)-1H-1,2,4-triazol-5-yl]-2-pyridinecarbonitrile
CAS Number
577778-58-6
Synonyms
  • FYX-051
Molecular Formula
C13H8N6
Formula Weight
248.2
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 20 mg/mlDMF:PBS (pH 7.2) (1:5): 0.16 mg/mlDMSO: 10 mg/ml
λmax
208, 272 nm
SMILES
N#CC1=CC(C2=NN=C(C3=CC=NC=C3)N2)=CC=N1
InChi Code
InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19)
InChi Key
UBVZQGOVTLIHLH-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $75

    Add

    10 mg

    $134

    Add

    50 mg

    $589

    Add

    100 mg

    $882

    Add
    Product Description

    Topiroxostat is an inhibitor of xanthine oxidoreductase (IC50 = 5.3 nM).1 It inhibits ATP-binding cassette transporter 2 (ABCG2) in isolated human plasma (IC50 = 0.18 µM).2 Topiroxostat (5 µM) also increases LPS-induced decreases in B cell lymphoma 2 (Bcl-2) levels and decreases LPS-induced increases of Bax and cleaved caspase-3 levels in H9c2 rat cardiomyocytes.3 Chronic administration of topiroxostat results in the presence of urinary xanthine crystals and induces nephropathy in rats when administered at doses of 0.2 and 1 mg/kg, respectively.4 Formulations containing topiroxostat have been used in the treatment of gout and hyperuricemia.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Sato, T., Ashizawa, N., Matsumoto, K., et al. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia. Bioor. Med. Chem. Lett. 19(21), 6225-6229 (2009).

    2. Miyata, H., Takada, T., Toyoda, Y., et al. Identification of febuxostat as a new strong ABCG2 inhibitor: Potential applications and risks in clinical situations. Front. Pharmacol. 7(518), (2016).

    3. Liu, J., Zhang, X., Lao, Y., et al. Protective effect of topiroxostat on myocardial injury induced by lipopolysaccharide. J. Surg. Res. 271, 171-179 (2022).

    4. Shimo, T., Ashizawa, N., Moto, M., et al. FYX-051, a xanthine oxidoreductase inhibitor, induces nephropathy in rats, but not in monkeys. Toxicol. Pathol. 37(4), 438-445 (2009).